Neuraxis expands at-the-market stock offering to $11.5M
Neuraxis, Inc. increased the capacity of its existing at-the-market stock offering program.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Neuraxis, Inc. increased the capacity of its existing at-the-market stock offering program. The company may now sell shares of its common stock for an aggregate offering price of up to $11,500,000 through Craig-Hallum Capital Group LLC under a previously effective Form S-3 shelf registration.
The agreement was originally sized at up to $6,270,000. From August 29, 2025 through April 20, 2026, Neuraxis sold 1,125,281 shares of common stock under this arrangement. A new prospectus supplement and a related legal opinion from Lucosky Brookman LLP support the expanded program.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
ATM program original size: $6,270,000 aggregate offering price
Shares sold to date: 1,125,281 shares
ATM program expanded size: $11,500,000 aggregate offering price
3 metrics
ATM program original size
$6,270,000 aggregate offering price
Initial At The Market Offering Agreement capacity
Shares sold to date
1,125,281 shares
Common stock sold from August 29, 2025 through April 20, 2026
ATM program expanded size
$11,500,000 aggregate offering price
Maximum common stock sales under amended At The Market Offering Agreement
Key Terms
At The Market Offering Agreement, at the market offering, Registration Statement on Form S-3, prospectus supplement, +1 more
5 terms
At The Market Offering Agreement financial
"the Company entered into an At The Market Offering Agreement (the “Agreement”) with Craig-Hallum Capital Group LLC"
An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.
at the market offering financial
"by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4)"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
Registration Statement on Form S-3 regulatory
"under the Company’s effective Registration Statement on Form S-3 (File No. 333-283798)"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
prospectus supplement regulatory
"the prospectus supplement relating to this offering, filed on August 29, 2025"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Neuraxis (NRXS) change in its at-the-market offering on April 21, 2026?
Neuraxis increased the capacity of its at-the-market common stock offering to a total aggregate offering price of $11,500,000. This expansion continues under its existing Form S-3 registration and agreement with Craig-Hallum Capital Group LLC as sales agent.
How much stock has Neuraxis (NRXS) already sold under its at-the-market program?
From August 29, 2025 through April 20, 2026, Neuraxis sold 1,125,281 shares of its common stock under the at-the-market agreement. These sales were made pursuant to the company’s effective Form S-3 shelf registration and related prospectus supplements.
What was the original size of Neuraxis (NRXS) at-the-market equity program?
The at-the-market offering agreement initially allowed Neuraxis to sell common stock with an aggregate offering price of up to $6,270,000. The April 21, 2026 prospectus supplement amended the program to increase the maximum aggregate offering capacity to $11,500,000.
Which registration statement covers Neuraxis (NRXS) at-the-market stock sales?
Neuraxis conducts its at-the-market common stock sales under an effective Registration Statement on Form S-3, File No. 333-283798. This registration statement was filed on December 13, 2024 and declared effective on February 11, 2025, supporting ongoing sales.
Who acts as sales agent for Neuraxis (NRXS) at-the-market offering?
Craig-Hallum Capital Group LLC serves as the sales agent under Neuraxis’ At The Market Offering Agreement. The agent may effect sales of Neuraxis common stock from time to time, including through transactions deemed an “at the market offering” under Rule 415(a)(4).
What legal opinion supports Neuraxis (NRXS) expanded at-the-market offering?
A legal opinion from Lucosky Brookman LLP addresses the legality of issuing and selling Neuraxis common stock under the at-the-market agreement. This opinion is filed as Exhibit 5.1, with an associated consent included in Exhibit 5.1 and referenced as Exhibit 23.1.
AI-generated analysis. How Rhea-AI works. Not financial advice.
